MGI Tech Co. Ltd. A
MGI Tech Co., Ltd. engages in the research, development, production, and sale of DNA sequencing instruments, reagents, and related products for precision medicine, agriculture, healthcare, and other relevant industries in China and internationally. Its products include sequencers, such as genetic sequencers, sequencing reagents, library prep kits multiplex immunofluorescence reagent staining sets… Read more
MGI Tech Co. Ltd. A (688114) - Net Assets
Latest net assets as of June 2025: CN¥7.74 Billion CNY
Based on the latest financial reports, MGI Tech Co. Ltd. A (688114) has net assets worth CN¥7.74 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥10.26 Billion) and total liabilities (CN¥2.52 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥7.74 Billion |
| % of Total Assets | 75.47% |
| Annual Growth Rate | 22.16% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 58.28 |
MGI Tech Co. Ltd. A - Net Assets Trend (2020–2024)
This chart illustrates how MGI Tech Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MGI Tech Co. Ltd. A (2020–2024)
The table below shows the annual net assets of MGI Tech Co. Ltd. A from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥7.89 Billion | -9.02% |
| 2023-12-31 | CN¥8.67 Billion | -8.23% |
| 2022-12-31 | CN¥9.45 Billion | +131.98% |
| 2021-12-31 | CN¥4.07 Billion | +14.98% |
| 2020-12-31 | CN¥3.54 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to MGI Tech Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 112212034934.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥8.95 Billion | 113.46% |
| Total Equity | CN¥7.89 Billion | 100.00% |
MGI Tech Co. Ltd. A Competitors by Market Cap
The table below lists competitors of MGI Tech Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MFF Capital Investments Ltd
AU:MFF
|
$1.26 Billion |
|
Bufab Holding AB
ST:BUFAB
|
$1.26 Billion |
|
Nomad Foods Ltd
NYSE:NOMD
|
$1.26 Billion |
|
Radiant Opto-Electronics Corp
TW:6176
|
$1.26 Billion |
|
goeasy Ltd
PINK:EHMEF
|
$1.25 Billion |
|
Hangzhou Robam Appliances Co Ltd
SHE:002508
|
$1.25 Billion |
|
COVIVIO HOTELS INH. EO 4
F:9FM
|
$1.25 Billion |
|
Lithium Americas Corp
NYSE:LAC
|
$1.25 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MGI Tech Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 8,634,440,859 to 7,890,161,750, a change of -744,279,109 (-8.6%).
- Net loss of 600,827,021 reduced equity.
- Dividend payments of 24,167,597 reduced retained earnings.
- Other factors decreased equity by 119,284,491.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-600.83 Million | -7.61% |
| Dividends Paid | CN¥24.17 Million | -0.31% |
| Other Changes | CN¥-119.28 Million | -1.51% |
| Total Change | CN¥- | -8.62% |
Book Value vs Market Value Analysis
This analysis compares MGI Tech Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.84x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.75x to 2.84x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | CN¥9.36 | CN¥53.79 | x |
| 2021-12-31 | CN¥10.78 | CN¥53.79 | x |
| 2022-12-31 | CN¥22.72 | CN¥53.79 | x |
| 2023-12-31 | CN¥20.77 | CN¥53.79 | x |
| 2024-12-31 | CN¥18.94 | CN¥53.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MGI Tech Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.61%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -19.94%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.31x
- Recent ROE (-7.61%) is below the historical average (5.29%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 7.49% | 9.38% | 0.45x | 1.77x | CN¥-87.21 Million |
| 2021 | 12.07% | 12.31% | 0.66x | 1.48x | CN¥82.89 Million |
| 2022 | 21.53% | 47.90% | 0.38x | 1.19x | CN¥1.09 Billion |
| 2023 | -7.04% | -20.87% | 0.28x | 1.22x | CN¥-1.47 Billion |
| 2024 | -7.61% | -19.94% | 0.29x | 1.31x | CN¥-1.39 Billion |
Industry Comparison
This section compares MGI Tech Co. Ltd. A's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,879,733,462
- Average return on equity (ROE) among peers: 24.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MGI Tech Co. Ltd. A (688114) | CN¥7.74 Billion | 7.49% | 0.32x | $1.26 Billion |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $792.82 Million | 25.77% | 0.17x | $318.98 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $482.51 Million | 20.84% | 0.32x | $2.79 Billion |
| Double Medical Technology Inc (002901) | $224.61 Million | 43.10% | 0.32x | $404.40 Million |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $1.42 Million | 98.49% | 2.27x | $281.14 Million |
| Lepu Medical Tech Beijing (300003) | $12.27 Billion | 14.01% | 0.69x | $2.71 Billion |
| INKON Life Technology Co Ltd (300143) | $1.81 Billion | -20.17% | 0.37x | $637.77 Million |
| Edan Instruments Inc (300206) | $1.26 Billion | 7.37% | 0.15x | $501.55 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $504.27 Million | 13.31% | 0.36x | $360.97 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.44 Billion | 2.82% | 0.20x | $267.10 Million |
| Sinocare Inc (300298) | $17.42 Million | 41.15% | 0.68x | $952.60 Million |